© 2026 Nuvex Media LLC. All rights reserved. MarketSpeaker is part of Nuvex Media, a global next-gen media network.

Warren Buffett Steps Down After 60 Years, Hands Berkshire Hathaway Reins to Greg Abel

Warren Buffett will step aside as CEO of Berkshire Hathaway this week after six decades, marking the end of one of the most successful leadership tenures in corporate history.

By Michael Foster | Edited by Oleg Petrenko Published: Updated:
Warren Buffett Steps Down After 60 Years, Hands Berkshire Hathaway Reins to Greg Abel
Warren Buffett is set to relinquish the CEO role at Berkshire Hathaway this week, closing a 60-year run that ranks among the most successful leadership tenures in corporate history. Photo: Oleg Petrenko / MarketSpeaker

Warren Buffett will officially step down as chief executive of Berkshire Hathaway on Wednesday, closing a remarkable 60-year chapter that transformed a struggling textile company into one of the world’s most valuable investment conglomerates.

Buffett, now 95, announced earlier in May 2025 that he planned to relinquish the CEO role by year-end. His departure comes with Berkshire Hathaway shares trading near record levels and the company firmly embedded in the global financial system. Leadership will pass to Greg Abel, a long-prepared successor who has overseen Berkshire’s non-insurance operations since 2018.

Under Buffett’s stewardship, Berkshire Hathaway shares climbed from just $19 in 1965 to roughly $750,000 today, representing a gain of approximately 3,950,000%. The performance cemented Buffett’s reputation as the most influential long-term investor of the modern era and reshaped how generations of investors think about capital allocation, patience, and risk.

Six Decades of Compounding and Discipline

Buffett’s success rested on a disciplined value-investing philosophy combined with an unusually long time horizon. Rather than chasing trends, he focused on durable businesses, strong management teams, and predictable cash flows. Over decades, that approach produced a sprawling portfolio spanning insurance, railroads, energy, manufacturing, consumer brands, and major equity stakes.

Berkshire’s insurance float became the engine of its compounding machine, allowing Buffett to deploy capital at scale during market dislocations. From the financial crisis to pandemic-era volatility, Berkshire repeatedly emerged stronger, often acting as a buyer of last resort when markets were under stress.

As of December 30, 2025, Buffett’s personal net worth is estimated at $149 billion, placing him among the world’s richest individuals. Yet his public image has remained rooted in restraint. He still lives in the same Omaha home he bought decades ago, favors McDonald’s and Coca-Cola, and is known for spending roughly six hours a day reading.

What Comes Next for Berkshire Hathaway

Greg Abel inherits a company with immense scale, a fortress balance sheet, and more than $150 billion in cash and equivalents. Prepared for the role since at least 2021, Abel is widely viewed as a steady operator rather than a capital-markets celebrity, signaling continuity rather than disruption.

Investors will now closely watch how Berkshire deploys capital without Buffett’s direct hand, particularly in acquisitions and large equity investments. While Buffett will remain chairman for a transition period, the psychological shift for markets is significant.

The end of Buffett’s tenure marks more than a leadership change. It closes an era in which one individual became synonymous with disciplined investing, long-term thinking, and trust-based shareholder relationships. Berkshire Hathaway now enters its next phase carrying an extraordinary legacy and the challenge of sustaining it.

Big Tech & Innovation, Business, News
Related Articles

Microsoft Loses OpenAI Exclusivity as Partnership Terms Shift

Microsoft will lose exclusive rights to OpenAI models, allowing broader distribution as the partnership evolves and revenue-sharing terms change.

By Daniel Wright | Edited by Oleg Petrenko Published: Updated:
Microsoft Loses OpenAI Exclusivity as Partnership Terms Shift
Microsoft will give up exclusive rights to OpenAI models, enabling broader distribution as the partnership evolves and revenue-sharing terms shift. Photo: Matthew Manuel / Unsplash

Microsoft is set to lose its exclusive rights to distribute OpenAI’s models, marking a significant shift in one of the most closely watched partnerships in the artificial intelligence industry.

Under the updated agreement, Microsoft will retain access to OpenAI technology through 2032, but the exclusivity clause has been removed, allowing OpenAI to offer its models through other cloud providers.

The change signals a new phase in the relationship, reflecting evolving priorities for both companies as competition intensifies across the AI landscape.

OpenAI Gains Flexibility as Deal Terms Evolve

The removal of exclusivity allows OpenAI to expand its distribution strategy and pursue partnerships with other major cloud providers, including rivals to Microsoft.

Previously, reliance on a single partner limited OpenAI’s ability to negotiate broader commercial agreements and scale its offerings across different platforms.

The revised terms also reshape the financial structure of the partnership. Microsoft will no longer receive a share of OpenAI’s revenue, while OpenAI will continue to pay Microsoft 20% of its revenue until 2030, subject to a capped amount.

As previously covered, the AI sector has seen rapid shifts in partnership dynamics as companies seek greater flexibility and control over their technologies.

The new arrangement positions OpenAI to diversify its revenue streams and reduce dependency on a single distribution channel.

Market Implications Highlight Intensifying Cloud AI Competition

The move is expected to intensify competition among cloud providers, as companies like Amazon and Google gain potential access to OpenAI’s models.

For Microsoft, the loss of exclusivity may weaken a key competitive advantage in its Azure cloud business, which has benefited from tight integration with OpenAI technologies.

At the same time, Microsoft retains long-term access to the models, ensuring continuity for its enterprise customers and AI-driven products.

Investors are likely to view the development as a rebalancing of power within the partnership, with OpenAI gaining greater independence while Microsoft shifts toward a more traditional vendor relationship.

For markets, the change underscores a broader trend: AI partnerships are becoming more fluid, with companies prioritizing flexibility and ecosystem expansion over exclusive arrangements.

The evolution of the Microsoft–OpenAI relationship will be closely watched as a key indicator of how competition in the AI and cloud sectors continues to develop.

Big Tech & Innovation, Business, News
Related Articles

U.S. Government’s Intel Stake Gains $25.7 Billion in Eight Months After CHIPS Investment

A U.S. government investment in Intel has generated $25.7 billion in unrealized gains in just eight months after shares surged following earnings.

By Benjamin Harper | Edited by Oleg Petrenko Published:
U.S. Government’s Intel Stake Gains $25.7 Billion in Eight Months After CHIPS Investment
A U.S. government investment in Intel has produced $25.7 billion in unrealized gains in just eight months as the stock surged following earnings. Photo: Louis Velazquez / Unsplash

A U.S. government investment in Intel has generated approximately $25.7 billion in unrealized gains in just eight months, following a sharp rally in the chipmaker’s stock after its latest earnings report.

The position stems from an $8.9 billion investment made in August 2025 at a price of $20.47 per share, giving the government a roughly 10% passive stake in the company.

Since then, Intel shares have surged, briefly reaching around $80 in after-hours trading following strong results, significantly boosting the value of the stake to approximately $34.6 billion.

CHIPS Act Strategy Shifted Toward Equity Ownership

The investment represents a notable shift in how the U.S. government deploys industrial policy, converting traditional grant funding into an equity stake.

Instead of issuing direct subsidies, the administration structured the funding as a capital investment, combining $5.7 billion in CHIPS Act grants with an additional $3.2 billion from the Secure Enclave defense program.

The result was the purchase of approximately 433.3 million shares, without board representation or management control, effectively making the government a passive investor.

At the time of the deal, Intel shares were trading near $24 and had fallen roughly 60% from their 2024 highs, with analysts viewing the move as a potential stabilization effort.

As previously covered, governments globally have been increasing support for semiconductor manufacturing as part of broader efforts to secure supply chains and strengthen domestic production.

Market Implications Highlight New Model for Industrial Policy

The scale of the gains has sparked debate over whether equity-based interventions could become a more common tool in economic policy.

From a financial perspective, the returns – equivalent to more than $25 billion on paper – outpace the performance of many hedge funds over comparable periods.

However, analysts caution that the gains remain unrealized and are subject to market volatility, particularly in the cyclical semiconductor sector.

For investors, the development underscores the growing intersection between government policy and capital markets, especially in strategic industries like semiconductors.

The approach may influence future policy decisions, particularly as governments seek to balance economic support with potential financial returns.

The Intel case highlights a broader trend: industrial policy is evolving beyond subsidies toward more market-oriented mechanisms, with implications for both public finances and private sector dynamics.

Economy, Geopolitics & Policy, News
Related Articles

China Blocks Meta’s $2 Billion Acquisition of AI Startup Manus

China has blocked Meta’s $2 billion acquisition of AI startup Manus, citing regulatory concerns over the cross-border deal.

By Michael Foster | Edited by Oleg Petrenko Published:
China Blocks Meta’s $2 Billion Acquisition of AI Startup Manus
China has blocked Meta’s $2 billion acquisition of AI startup Manus, citing regulatory concerns over the cross-border transaction. Photo: Oleg Petrenko / MarketSpeaker

China has blocked Meta’s planned $2 billion acquisition of AI startup Manus, marking a significant regulatory intervention in a cross-border technology deal.

The decision reflects increasing scrutiny from Chinese authorities over foreign acquisitions involving companies with domestic ties, particularly in sensitive sectors such as artificial intelligence.

Manus, a Singapore-based startup with Chinese roots, had been seen as a strategic addition to Meta’s expanding AI capabilities.

Regulatory Concerns Intensify Around AI Deals

Chinese regulators have been tightening oversight of technology transactions, especially those involving data, advanced computing, and AI-related intellectual property.

The move to block the deal highlights concerns around data security, technological sovereignty, and the potential transfer of sensitive capabilities to foreign firms.

For Meta, the acquisition was expected to strengthen its position in the competitive AI landscape, where companies are racing to secure talent and technology.

As previously covered, governments globally are increasing regulatory scrutiny of AI and tech deals, reflecting the strategic importance of these assets.

The decision also underscores geopolitical tensions that continue to shape cross-border investment flows in the technology sector.

Market Implications Highlight Growing Deal Uncertainty

The blocked transaction adds to uncertainty for companies pursuing international expansion through acquisitions, particularly in regulated markets.

Investors may view the decision as a signal that regulatory risks are rising, potentially complicating future deal-making in AI and related industries.

For Meta, the setback could delay its efforts to expand its AI capabilities through external acquisitions, increasing reliance on internal development or alternative partnerships.

At the same time, the broader AI investment trend remains strong, with companies continuing to deploy capital despite regulatory headwinds.

For markets, the development reinforces a key theme: geopolitical and regulatory factors are playing an increasingly important role in shaping the trajectory of the global technology sector.

The outcome may influence how companies structure future deals, particularly those involving sensitive technologies and cross-border operations.

Economy, Geopolitics & Policy, News
Related Articles

SanDisk Shares Surge 3000% as AI Boom Drives Data Center Demand

SanDisk shares have surged 3000% over the past year as demand for AI data center storage fuels explosive growth.

By Daniel Wright | Edited by Oleg Petrenko Published:
SanDisk Shares Surge 3000% as AI Boom Drives Data Center Demand
SanDisk shares have jumped 3000% over the past year, driven by surging demand for data center storage powering AI growth. Photo: SanDisk / X

SanDisk shares have surged approximately 3000% over the past year, pushing the company’s market capitalization to around $154 billion as the artificial intelligence boom drives unprecedented demand for data center storage.

While widely known for consumer products such as USB flash drives, SanDisk has emerged as a key supplier of memory solutions critical for AI infrastructure, particularly in large-scale data centers.

The rally highlights how the AI boom is extending beyond chipmakers like Nvidia into broader segments of the technology supply chain.

AI Infrastructure Demand Fuels Memory Market Expansion

SanDisk’s growth is being driven by rising demand for high-performance storage solutions required to support AI workloads, including training and inference of large models.

Data centers rely heavily on advanced memory systems to process and store massive volumes of data, making companies like SanDisk essential to the functioning of AI ecosystems.

As AI adoption accelerates across industries, the need for scalable and efficient storage infrastructure has increased sharply, benefiting memory manufacturers.

As previously covered, the AI investment cycle has expanded to include not only chips but also complementary technologies such as storage, networking, and power systems.

SanDisk’s transformation from a consumer-focused brand to a key infrastructure player reflects broader shifts in how value is being created in the tech sector.

Market Momentum Highlights Expanding AI Supply Chain Opportunities

The company’s sharp valuation increase underscores strong investor appetite for businesses positioned within the AI supply chain.

Analysts note that “picks and shovels” companies those providing essential components for AI – are increasingly seen as attractive investment opportunities alongside headline technology firms.

However, the scale of the rally also raises questions about sustainability, as rapid gains may reflect elevated expectations for future growth.

At the same time, competition in the memory market remains intense, with other global players also investing heavily to meet rising demand.

For investors, the key question is whether SanDisk can maintain its growth trajectory as AI infrastructure spending evolves and market dynamics shift.

The surge highlights a broader theme: the AI boom is reshaping multiple layers of the technology stack, creating winners across a wide range of industries beyond traditional chipmakers.

Markets, News, Stocks
Related Articles

Eli Lilly to Acquire Ajax Therapeutics in Deal Worth Up to $2.3 Billion

Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, strengthening its pipeline in blood cancer treatments.

By Emma Clarke | Edited by Oleg Petrenko Published:
Eli Lilly to Acquire Ajax Therapeutics in Deal Worth Up to $2.3 Billion
Eli Lilly is set to acquire Ajax Therapeutics for up to $2.3 billion, bolstering its pipeline in blood cancer treatments. Photo: Eli Lilly / Facebook

Eli Lilly has agreed to acquire privately held Ajax Therapeutics in a deal valued at up to $2.3 billion, as the pharmaceutical giant moves to strengthen its position in oncology.

The all-cash transaction will give Lilly access to Ajax’s pipeline of therapies targeting blood cancers, including conditions such as myelofibrosis and polycythemia vera.

The deal reflects Lilly’s broader strategy of expanding its portfolio through targeted acquisitions of early-stage biotech firms with promising drug candidates.

Acquisition Targets High-Growth Oncology Segment

Ajax Therapeutics specializes in developing treatments for hematologic malignancies, an area of increasing focus for major pharmaceutical companies due to strong demand and high unmet medical needs.

By acquiring Ajax, Lilly gains access to novel therapies that could complement its existing oncology pipeline and accelerate development in targeted cancer treatments.

The structure of the deal includes upfront payments and potential milestone-based payouts, a common approach in biotech acquisitions that aligns cost with development progress.

As previously covered, large pharmaceutical companies have been активно pursuing acquisitions to replenish pipelines and maintain growth as patent expirations approach.

The move also underscores the importance of precision medicine and targeted therapies in the future of cancer treatment.

Market Implications Highlight Ongoing Pharma Consolidation

The acquisition reflects continued consolidation in the pharmaceutical industry, where companies are seeking to scale research capabilities and diversify treatment portfolios.

Investors often view such deals as a way to secure long-term growth, particularly when focused on high-potential therapeutic areas like oncology.

However, the success of the acquisition will depend on clinical trial outcomes, regulatory approvals, and the commercial viability of Ajax’s drug candidates.

At the same time, rising deal activity highlights the competitive landscape, with major players competing for access to innovative biotech assets.

For markets, the transaction reinforces a key theme: pharmaceutical companies are increasingly relying on external innovation to drive growth and maintain competitive positioning.

Lilly’s ability to integrate Ajax’s pipeline and bring new treatments to market will be a critical factor in determining the long-term value of the deal.

Big Tech & Innovation, Business, News
Related Articles